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Summary
Twelve weeks sofosbuvir/velpatasvir (SOF/VEL) is a highly effective pan-genotypic 
regimen for hepatitis C. Phase 2 data suggest 8 weeks of treatment may be suf-
ficient for previously untreated noncirrhotic patients with genotype 3 (GT3) infec-
tion. To maximize the number of patients potentially cured within a fixed treatment 
budget, we elected to treat such patients locally eligible for treatment (F2/3), 
with 8 weeks of SOF/VEL. By local protocol, treatment-naive patients with F2 
(LSM > 6.9kPa < 9.5kPa) or F3 fibrosis (≥9.5kPa < 12.5kPa) were eligible for 8-week 
SOF/VEL treatment. Patients commencing treatment before 1 Oct 2017 were 
identified from the Scottish HCV database. Baseline and treatment outcome data 
obtained. Ninety patients were included for analysis (72 (80%) male, mean age 45 
(IQR ± 8.4), 28 (31.1%) F3 fibrosis). Opioid agonist therapy (OAT) was prescribed in 82 
(91.1%) patients. Of 49 patients attending Glasgow city Alcohol and Drug Services, 
27 (55.1%) had evidence of recent drug use (< 3 months) including 8 (16.3%) with self-
reported intravenous drug use. On an intention-to-treat basis, SVR rates were 86/90 
(95.6%, 95% CI 89.0-98.8). Excluding those who prematurely discontinued treatment 
(n = 4), died prior to SVR testing (n = 1) or whom experienced reinfection (n = 1), per-
protocol SVR rate was 84/84 (100%, 95% CI 95.7-100.0). In conclusion, eight-week 
SOF/VEL is highly effective in treatment-naive GT3 patients with significant fibrosis. 
This offers a non-protease inhibitor-based 8-week regimen which may be useful for 
complex drug interactions or where time-limited opportunity for treatment. In lim-
ited resource settings, reduction in drug acquisition costs may help achieve progress 
towards the goal of HCV elimination.
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1  | INTRODUC TION
Sofosbuvir/velpatasvir (SOF/VEL) is a highly effective pan-genotypic 
hepatitis C regimen, with high rates of sustained viral response (SVR) 
amongst those treated for genotype 3 (GT3) infection.1 In phase 2 
trials, 8 weeks of SOF/VEL was highly effective in treating noncir-
rhotic patients with GT32 but not genotype 1 infection.3
Genotype 3 accounts for around half of HCV infections in 
Scotland. In November 2017, Scottish National HCV guidelines were 
updated to advocate direct-acting antiviral (DAA) treatment for all 
patients with HCV. Prior to this, and at the time of the approval of 
SOF/VEL by the Scottish Medicines Consortium in November 2016,4 
interferon-free DAA regimens for patients with GT3 infection were 
restricted to those with F2 fibrosis and above, or those with signif-
icant extra-hepatic manifestations. Our health board (NHS Greater 
Glasgow and Clyde) initiates around 40% of hepatitis C treatments 
in Scotland and allocates a fixed budget for drug costs. This budget 
is sufficient to meet the Scottish Government minimum treatment 
targets. However, with judicious spending, more patients may po-
tentially be treated. In order to maximize treatment numbers, and 
taking into account the available in vitro and phase 2 data, our local 
HCV treatment guideline committee elected to mandate that treat-
ment-naive noncirrhotic GT3 patients eligible for treatment (F2/3 or 
F0/1 with significant extra-hepatic manifestations) be treated with 
8 weeks of SOF/VEL. Here, we report the results from the initial 
cohort of patients treated in Glasgow treatment centres using this 
regimen.
2  | MATERIAL S AND METHODS
By local treatment protocol, all treatment-naive patients with F2 
or F3 fibrosis commencing treatment from January 2017 received 
treatment with 8 weeks of SOF/VEL, unless contraindicated, or in 
the presence of insurmountable drug-drug interactions. For HCV-
monoinfected patients, F2 was defined by liver stiffness meas-
urements (LSM) >6.9kPa and <9.5kPa, and F3 by LSM ≥9.5kPa 
& <12.5kPa. For HIV co-infected patients, the lower cut-offs of 
≥6.5 kPa and <8.8 kPa and ≥8.8 kPa and <11.9 kPa were used for F2 
and F3 fibrosis, respectively. As is our standard practice for DAAs, 
SOF/VEL was dispensed via community pharmacies. For patients on 
opioid agonist therapy (OAT), DAAs were dispensed according to 
OAT prescription (daily observed therapy (DOT) vs non-DOT).
The Scottish Hepatitis C Database is a national database that 
holds data on all patients attending HCV services in Scotland, as well 
as ethics approval for conducting research including on treatment 
outcome. The database was used to identify all noncirrhotic pa-
tients commencing treatment with SOF/VEL, in Glasgow treatment 
centres, with intended treatment duration of 8 weeks prior to 31st 
September 2017. Non-GT3 patients were excluded. Baseline data 
on age, gender, LSM and virological response were obtained. Testing 
for HCV RNA was carried out by a single laboratory using the Abbot 
realtime assay, with a lower limit of quantification of 12IU/ml. Where 
relevant, DAA dispensing data (DOT vs non-DOT) were obtained 
from pharmacy prescription records. For patients on OAT prescribed 
by Glasgow City Alcohol and Drug Services, data on history of drug 
TA B L E  1   Baseline Characteristics and drug use
Demographics n = 90
Male (%) 72 (80)
Mean age (SD) 45 (±8.4)
Fibrosis stage  F0/1 (LSM < 6.9kPa) 2 (2.2)
F2 (LSM > 6.9 & <9.5kPa) 60 (66.7)
F3 (LSM ≥ 9.5 & <12.5kPa) 28 (31.1)
Mean LSM (SD) 8.8 (±1.5)
Mean viral load (SD) 5.7 log iu/ml (±0.9)
Viral load > 6.77 log iu/ml(6 million) 6 (6.6%)
Co-infection HIV 3 (3.3)
HBV 1 (1.1)
Incarcerated 5 (5.5)
On OAT 82 (91.1)
Daily supervised OAT 38 (42.2)
Drug use for those attending Glasgow City Alcohol and Drug Servicesa n = 49
Self-reported IV drug use 8 (16.3%)
Self-reported non-IV drug use 14 (28.6%)
No self-reported drug use, but positive urine toxicology 5 (10.2%)
Evidence of drug use (self-reported or urine toxicology) 27 (55.1%)
Abbreviations: IV, intravenous; OAT, opioid agonist therapy.
aDrug use figures were only available for patients attending Glasgow City Alcohol and Drug Services (n = 49). 
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use were obtained from the database and augmented by review of 
community case notes. Self-reported intravenous and nonintrave-
nous drug use were noted, as was unreported drug use evident by 
positive urine toxicology for nonprescribed drugs of abuse (DOA). 
Sustained viral response (SVR) was defined by an HCV PCR test less 
than the lower level of quantification at 12 weeks or more after the 
end of treatment.
SVR rates were examined on an intention-to-treat basis, com-
prising every patient meeting the inclusion criteria who commenced 
treatment. A second per-protocol analysis was undertaken, including 
only those who completed 8 weeks of treatment as scheduled, and 
excluding those patients with missing SVR data, or whom experi-
enced reinfection.
3  | RESULTS
Ninety-two patients met the inclusion criteria. Two were subse-
quently excluded; one with persistent low level viraemia who was 
unable to be genotyped (successfully treated with 8 weeks of SOF/
VEL) and one incarcerated patient who was transferred to another 
prison where 12 weeks of treatment was given according to local 
protocol.
Therefore, 90 patients were included in our analysis. Baseline 
data (Table 1) show a cohort that are predominantly male (80%), and 
in their 40s (mean age 45 years). Just under one third (28 (31.1%)) 
had F3 fibrosis. OAT was co-prescribed in 82 (91.1%) patients. 
Forty-nine (54.4%) were receiving OAT via Glasgow City Alcohol and 
Drug Services, of whom 27 (55.1%) had evidence of drug use in the 
3 months prior to treatment, including 8 (16.3%) with self-reported 
intravenous drug use.
End of treatment results were available for 82 (91.1%) patients 
and demonstrated that approximately one in four patients had de-
tectable RNA, either below the level of quantification (16, 17.8%) or 
quantifiable (7, 7.8%; range 12-41 IU/mL).
Four patients discontinued treatment prematurely. Of these, 
2 who discontinued at 6 weeks (early liberation) and 4 weeks 
(noncompliance) failed to achieve SVR. The other 2 patients, who 
both discontinued at 6 weeks (1 due to ICU admission and 1 due to 
noncompliance), achieved SVR. One patient died after the end of 
treatment of a drug overdose —prior to SVR12 time point. A further 
patient was negative at the end of treatment but demonstrated low 
level viraemia at SVR12 point (184 IU/mL) in the context of ongoing 
intravenous drug use. Further testing was negative beyond SVR 24 
time point, and the patient was felt likely to have had reinfection 
with spontaneous clearance.
On an intention-to-treat basis, SVR rates were 86/90 (95.6%, 
95% CI 89.0-98.8). Excluding those who prematurely discontinued 
treatment, died prior to SVR testing or whom experienced rein-
fection, the per-protocol SVR rate was 84/84 (100%, 95% CI 95.7-
100.0) (Figure 1).
4  | DISCUSSION
Amongst untreated patients with genotype 3 (GT3) infection, 98% of 
noncirrhotic patients achieved SVR when treated for 12 weeks with 
SOF/VEL.1 Such high SVR rates raised the question as to whether 
shorter treatment durations are possible. Sofosbuvir given in combi-
nation with the NS5a inhibitor ledipasvir for 8 weeks has been shown 
to be highly effective in treating noncirrhotic patients with genotype 
1 infection.5 In vitro, velpatasvir has similar potency against geno-
type 3 virus (EC50 0.004 nmol
ɑ,6 as ledipasvir has against genotype 
1a virus (EC50 0.031 nmol
ɑ7). In addition, phase 2 data demonstrated 
high SVR rates amongst noncirrhotic patients with GT3 infection 
treated for 8 weeks.2 Specifically, 98.1% (52/53) of GT3 patients 
treated for 8 weeks with the licensed dose of SOF/VEL (with or with-
out ribavirin) achieved SVR 12, with 1 patient withdrawing consent 
and no virological failures.
In the light of the available data, we speculated that 8-week SOF/
VEL would be an appropriate treatment regimen for noncirrhotic 
patients. In order to maximize the number of patients treated and 
cured of their hepatitis C, we took a pragmatic decision to treat for 
8 weeks. This off label treatment duration allowed us to treat three 
patients for the price of two treatments as per the label.
Our results confirm the efficacy of this approach with excel-
lent intention to treat (95.5%) and per-protocol (100%) results, and 
8 weeks is now the recommended duration for treatment-naive GT3 
patients with F0-3 disease in Scotland.8 Excellent results in a cohort 
of patients with significant drug use and high rates of OAT add to 
the growing body of evidence that current drug use is not a bar-
rier to successful HCV treatment.9 Two patients achieved SVR after 
6 weeks of treatment, one with F2 fibrosis (LSM 8.8 kPa, viral load 
6.7 log IU/ml) and one with F3 fibrosis (LSM 10.3 kPa, viral load 6.6 
log IU/ml), indicating that for some patients, successful treatment is 
possible with even shorter durations of therapy. However, a further 
two patients with abbreviated treatment failed to achieve SVR, one 
F2 patient with a high viral load treated for 4 weeks (LSM 7.4 kPa, 
viral load 6.91 log IU/mL) and one F3 patient with HIV co-infection 
treated for 6 weeks (LSM 11.0, viral load 3.43 log IU/mL). Further 
F I G U R E  1   Intention to treat and per-protocol SVR rates
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work is required to better characterize those for whom less than 
8 weeks of treatment is sufficient to achieve SVR.
Typically, a weakness of real-life cohorts is that of selection bias 
with uncertainty as to whether clinicians may direct patients with cer-
tain characteristics, favourable or unfavourable, towards a particular 
regimen. In our centres, all treatment-naive GT3 patients with F2/3 
fibrosis received 8 weeks of SOF/VEL. Deviation from this regimen 
was allowed only under exceptional circumstances (such as an insur-
mountable drug-drug interaction) and required independent review.
One undoubted weakness of our data is that it represents the 
effects of 8 weeks of SOF/VEL in treating GT3 within a single geo-
graphic location. Previous data from our group have demonstrated 
SVR rates for GT3 infection that are similar to registration trials 10-12; 
however, confirmation of our results from additional sites would be 
welcome. Whilst 90 patients may be viewed by some as a relatively 
small cohort, it is comparable with the 92 noncirrhotic GT3 patients 
included in the registration trial for the 8-week regimen of sofos-
buvir/velpatasvir/voxilaprevir.13 Likewise, whilst this cohort was 
enriched with patients with F2/3 fibrosis (as those with F0/1 were 
treatment eligible only if significant extra-hepatic manifestations of 
HCV), the number of patients with F3 fibrosis (28 (31.1%)) may give 
concern as to the efficacy in this subgroup. These numbers are sim-
ilar to the 29 GT1 patients with F3 fibrosis treated for 8 weeks with 
sofosbuvir/ledipasvir in ION-3,5 leading to an 8-week label and sub-
sequent real world validation of this approach. All of our F3 patients 
who completed 8 weeks of treatment achieved SVR. Our cohort did 
contain relatively few patients with a high baseline viral load (>6 mil-
lion IU/mL) and no patients with a viral load above 10 million IU/mL. 
Whilst all 5 patients >6 million IU/mL completing 8 weeks of treat-
ment achieved SVR, further data are required to confirm efficacy in 
this subgroup. After the period presented in this study, the first-line 
drug choice for genotype 3 patients in our centres changed to an 
alternative regimen (on cost basis following a national procurement 
tender process), limiting the ability to accrue more patients. Ongoing 
procurement rounds will likely lead to further opportunity to report 
on expanded numbers; however, we feel the current cohort is suffi-
cient to merit dissemination of our results.
Current European and American guidelines recommend 8 weeks 
of glecaprevir/pibrentasvir or 12 weeks of SOF/VEL as treatment 
options for GT3 noncirrhotic patients.14,15 Our real world results 
add to the phase 2 data suggesting that 8 weeks of SOF/VEL is suf-
ficient for this patient group. Implementation of such an approach 
would add a non-protease inhibitor-based 8-week regimen to the 
armamentarium. This may be relevant for individual patients with 
drug-drug interactions to protease inhibitor regimens. Equally, in 
situations where there is a time-limited opportunity to treat, or dos-
ing cannot always be reliably provided with food (such as prisons), a 
further 8-week option may be helpful. For patients who may be in 
contact with services intermittently or for brief periods of time such 
as those who are homeless or actively injecting drugs, an 8-week 
regimen lowers the barrier for treatment. Whilst there is a move to-
wards simplification and use of pan-genotypic regimens, anecdotally 
genotype is still checked in many countries.
Clinicians may use our data, in combination with phase 2 trials, 
to draw confidence in an 8-week regimen of SOF/VEL for GT3 in-
fection in treatment naïve patients without cirrhosis. Whilst further 
data are required for those with high viral loads, our data suggest 
that an 8-week regimen is applicable to a cohort of unselected pa-
tients. Such an approach may be beneficial in treating individual 
patients, and in some settings, may aid scale up of treatment by low-
ering the cost of therapy.
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